King Luther Capital Management Corp Purchases 22,345 Shares of Pfizer Inc. $PFE

King Luther Capital Management Corp boosted its position in Pfizer Inc. (NYSE:PFE) by 0.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,721,277 shares of the biopharmaceutical company’s stock after purchasing an additional 22,345 shares during the quarter. King Luther Capital Management Corp’s holdings in Pfizer were worth $65,964,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Pacer Advisors Inc. lifted its position in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi boosted its stake in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new position in Pfizer in the 1st quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. grew its holdings in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after acquiring an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.45 on Friday. The firm has a market cap of $138.99 billion, a price-to-earnings ratio of 13.00, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The stock has a fifty day simple moving average of $24.74 and a two-hundred day simple moving average of $24.37. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio is 100.00%.

Analyst Ratings Changes

Several analysts recently weighed in on PFE shares. Morgan Stanley reduced their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.18.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.